Pinnacle Associates Ltd. Purchases 9,269 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Pinnacle Associates Ltd. lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 60.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,630 shares of the company’s stock after buying an additional 9,269 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Prestige Consumer Healthcare were worth $1,776,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of PBH. First Trust Direct Indexing L.P. boosted its holdings in Prestige Consumer Healthcare by 18.5% during the first quarter. First Trust Direct Indexing L.P. now owns 4,422 shares of the company’s stock valued at $321,000 after acquiring an additional 689 shares during the period. Norden Group LLC grew its holdings in Prestige Consumer Healthcare by 40.6% in the 1st quarter. Norden Group LLC now owns 9,876 shares of the company’s stock valued at $717,000 after buying an additional 2,852 shares during the last quarter. Diversify Advisory Services LLC bought a new position in Prestige Consumer Healthcare in the 1st quarter worth approximately $419,000. Mirae Asset Global Investments Co. Ltd. increased its position in Prestige Consumer Healthcare by 6.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,579 shares of the company’s stock worth $1,929,000 after buying an additional 1,543 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Prestige Consumer Healthcare by 143.4% during the first quarter. BNP Paribas Financial Markets now owns 51,246 shares of the company’s stock worth $3,718,000 after buying an additional 30,191 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Trading Up 0.4 %

Shares of PBH stock opened at $74.05 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $56.61 and a 52-week high of $75.80. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of 18.11, a P/E/G ratio of 2.08 and a beta of 0.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The firm has a fifty day moving average of $72.17 and a 200-day moving average of $69.56.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The company had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. During the same quarter in the prior year, the company posted $1.06 EPS. The business’s revenue was down 4.4% on a year-over-year basis. On average, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.